Semi-annual Performance Forecast for 2026
Filed with SSE · · 2 pages · Chinese
Summary by 6ix AI
The company anticipates a net profit attributable to shareholders in the range of negative values, reflecting a significant decline compared to the previous year. The forecast highlights challenges such as a marketing transformation and increased fixed costs contributing to the anticipated losses. This preliminary forecast has not been audited by external accountants and is subject to change based on actual performance.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
On 6ix: 6ix.com/news/hainan-huluwa-pharmaceutical-group-co-ltdsemi-annual-performance-forecast-for-2026
Hainan Huluwa Pharmaceutical Group Co. Ltd. on 6ix
Earlier from Hainan Huluwa Pharmaceutical
- Announcement on Re-appointment of Accounting Firm for 2026
- Announcement on Obtaining Drug Registration Certificate by the Company and Its Wholly-owned Subsidiaries
- Announcement on Abnormal Fluctuations in Stock Trading
- Announcement on Progress in Implementing Other Risk Warnings for the Company's Stocks
- Announcement on Using Partial Idle Raised Funds to Temporarily Supplement Current Capital
Later from Hainan Huluwa Pharmaceutical
- Announcement on Undertakings by Controlling Shareholder and Actual Controller Not to Reduce Their Shareholdings in the Company
- Announcement on Receipt of the Administrative Penalty Decision by the Company and Relevant Responsible Persons
- Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report
- Announcement on Providing Guarantee for Wholly-owned Subsidiary
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
Follow Hainan Huluwa Pharmaceutical into a list and get an email when it puts out news.
Follow Hainan Huluwa Pharmaceutical